q&more
My watch list
my.chemie.de  
Login  

News

Simple and Fast Method for Radiolabelling Antibodies against Breast Cancer

Using UV light, radiolabelled antibodies can be produced in just 15 minutes

Jason P. Holland, UZH

Using UV light, radiolabelled antibodies can be produced in just 15 minutes.

24-Apr-2019: Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy. Researchers from the University of Zurich have created a new method for radiolabelling antibodies using UV light. In less than 15 minutes, the proteins are ready-to-use for cancer imaging or therapy.

Radioactive antibodies are used in nuclear medicine as imaging agents for positron emission tomography (PET) – an imaging technique that improves cancer diagnosis and monitoring of chemotherapy. Radioactive drugs can also be designed to kill tumors by delivering a radioactive payload specifically to the cancer cells. This treatment is called targeted radioimmunotherapy.

Photoradiolabelling: Radiochemistry in a flash

Conventional methods for radiolabelling proteins are time-consuming and difficult to automate. They require multi-step procedures in which the protein is purified, coupled to a metal-binding chemical substance, isolated, stored, and then radiolabelled. The team of Jason P. Holland, professor in the Department of Chemistry at the University of Zurich (UZH), has now established a new innovative method using UV light to synthesize radioactive drugs and diagnostic agents. “By combining photochemistry with radiochemistry, we are now able to make radiolabelled proteins much more quickly and easily – literally in a flash of light,” Holland says.

Metal-ion-binding and photoactivatable molecules

The UZH researchers produced a series of novel chemical compounds called chelates that have two distinctive properties: First, they are able to bind radioactive metal ions like gallium, copper and zirconium. Second, the molecules have a special chemical group that becomes activated by shining UV light on the sample. “The UV light causes the small metal complex to react extremely quickly and efficiently with certain amino acids found in proteins like antibodies,” Holland adds.

One-pot process in less than 20 minutes

The team was able to establish a one-pot process to radiolabel trastuzumab, an antibody used to treat patients with breast cancer, with gallium in less than 20 minutes. Remarkably, the photochemical conjugation was also successful using the prepared drug that is injected into the patient without pre-purification of the antibody. “The efficient one-pot route simplifies the production of radiolabelled proteins. It has the unique advantage of avoiding the need to isolate and characterize the conjugated intermediate antibody. And the process can be fully automated,” Holland stresses.

Radiolabelled antibodies for PET imaging

Time is one of the main challenges in radiotracer design for PET imaging. Since gallium, which is used frequently in nuclear medicine, decays rapidly, Holland’s team further developed their method using zirconium to radiolabel trastuzumab. They managed to synthesize the radiolabelled breast cancer antibody in high yield and purity in less than 15 minutes. With mice bearing human cancer cells that are targeted by trastuzumab, they showed that for PET imaging the zirconium-labelled antibody worked as well as those produced via established methods.

Patent application submitted

“Automated photoradiochemical synthesis has the potential to revolutionize the way in which radiolabelled antibodies and other proteins are used in science and medicine,” Jason P. Holland says. Therefore, he has submitted a patent application for the new procedure and aims to develop the technology along commercial lines. Furthermore, the researchers are expanding the technology for use against other cancers.

Original publication:
Malay Patra, Larissa S. Eichenberger, Gregor Fischer, and Jason P. Holland; "Photochemical conjugation and one-pot radiolabelling of antibodies for immuno-PET"; Angew. Chem.; December 5, 2018.
Larissa S. Eichenberger, Malay Patra and Jason P. Holland; "Photoactive chelates for radiolabelling proteins"; Chem. Commun.; December 21, 2018.
Malay Patra, Simon Klingler, Larissa S. Eichenberger and Jason P. Holland; "Simultaneous photoradiochemical labelling of antibodies for immuno-PET"; iScience (Cell Press); March 7, 2019.

Facts, background information, dossiers

  • antibodies
  • cancer cells
  • cancer
  • cancer diagnostics
  • positron emission t…
  • radioimmunotherapy

More about Universität Zürich

  • News

    Precise Decoding of Breast Cancer Cells Creates New Option for Treatment

    Researchers at the University of Zurich and from IBM Research have investigated the varying composition of cancer and immune cells in over one hundred breast tumors. They've found that aggressive tumors are often dominated by a single type of tumor cell. If certain immune cells are present ... more

    Water that never freezes

    Can water reach minus 263 degrees Celsius without turning into ice? Yes it can, say researchers from ETH Zurich and the University of Zurich, if it is confined in nanometre-scale lipid channels. Making ice cubes is a simple process: you take a plastic ice-cube tray like you’d find in most h ... more

    Bat Influenza Viruses Could Infect Humans

    Bats don’t only carry the deadly Ebola virus, but are also a reservoir for a new type of influenza virus. These newly discovered flu viruses could potentially also attack the cells of humans and livestock, researchers at the University of Zurich have now shown. Seasonal outbreaks of the flu ... more

  • q&more articles

    From the reveller to the lark

    Because of their genes, some people come into the world either as a lark (early riser) or a night-owl (late sleeper). In addition, however, even in normal people, such ”chronotype“ changes with age. Starting at puberty they develop into revellers. At the age of 20 a change occurs and the ... more

  • Authors

    Dr. Steven A. Brown

    Steven B. Brown studied biochemistry at Harvard College, Cambridge, Massachusetts, USA. In 1997 he received his doctorate in the Department of Biological Chemistry and Molecular Pharmacology, Harvard University, Cambridge, Massachusetts, USA. From 1998 – 2005 he was a postdoctoral fellow at ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE